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Summary 
The role of T cells expressing specific V/3 elements was examined in the regulation of allergen- 
specific immunoglobulin  (Ig)E production and airways responsiveness (AR). In BALB/c mice, 
inhalation  of the allergen ovalbumin (OVA) induced an IgE anti-OVA response, immediate cutaneous 
reactivity, and increased AR. These results were associated with an expansion of V/38.1/8.2 T 
cells in local draining lymph nodes of the airways and the lung.  Transfer  of V/38.1/8.2 T  cells 
from sensitized mice stimulated an IgE anti-OVA response, immediate cutaneous hypersensitivity, 
and increased AK in naive syngeneic recipients. In contrast, OVA-reactive V/32 T cells inhibited 
these effects. These data demonstrate for the first time that T cells with different VB specificities 
play a critical role in  the in vivo regulation  of allergen-specific IgE production  and AR. 
T  lymphocytes play a central role in the regulation of IgE 
production in vitro and in vivo. In addition to cognate 
T-B cell interaction (1, 2), II:4 is required for the generation 
of polyclonal and antigen-specific IgE responses (3-6), pri- 
marily by promoting Ig isotype switching (7). IgE levels are 
elevated in most allergic diseases,  and in the lung,  changes 
in airways responsiveness (AR) are associated with allergic 
responses. A  relationship between IgE and changes in AK 
is indicated by epidemiologic data linking asthma with IgE- 
related responses (8). To explore the interrelationship between 
T  cells,  IgE production,  and the pathogenesis  of AR,  we 
have developed a murine model of allergen-induced airways 
hyperresponsiveness (9). After inhalation of allergen (OVA), 
BALB/c but not SJL/J mice develop OVA-specific  IgE anti- 
bodies, immediate cutaneous reactivity to OVA, and an in- 
crease in AR, measured in tracheal smooth muscle prepara- 
tions. Further, these responses could be passively transferred 
to naive, syngeneic recipients by lymphocytes from peribron- 
chial lymph nodes (PBLN) of sensitized but not nonimmune 
mice (10). Sensitized PBLN are comprised of increased numbers 
of OVA-reactive T  cells  expressing V/38.1/8.2. 
In in vitro studies of the functional properties  of T  cell 
subsets  expressing  different  V/3  elements,  we  noted  that 
V/~8.1/8.2  T  cells  augmented  IgE  production  whereas 
VB2 + T  cells  limited  this increase  (11). We now demon- 
strate that transfer of V/38.1/8.2 T cells from sensitized animals 
can passively transfer the capacity to develop allergen-specific 
IgE, immediate cutaneous hypersensitivity, and altered AK 
in naive recipients, and that cotransfer of V/32 + T  cells pre- 
vents these responses.  These data demonstrate  that  T  cells 
bearing different V/3 elements are differentially involved in 
the in vitro and in vivo regulation  of IgE production  and 
affirm the link between IgE and altered AK. 
Materials  and Methods 
Sensitization Protocol.  BALB/c mice between 8 and 12 wk of 
age (The Jackson Laboratory, Bar Harbor, ME) were sensitized to 
OVA by inhalation  as described (9). Briefly, animals were sensi- 
tized by ultrasonic nebulization of 1% OVA (chicken OVA, grade 
V; Sigma Chemical Co., St. Louis, MO) diluted in sterile PBS. 
For this purpose five mice at a time were placed in a plastic chamber 
(22  x  23  x  14 cm), and the OVA solution was aerosolized into 
one end of the box by using an ultrasonic nebulizer (PulmoSonic 
25; DeVilbiss, Somerset, PA) at a continuous  air flow of 5 psi (1 
psi  =  6.9 kPa). At the other end of the chamber were two small 
holes to ensure continuous  air flow. With laser nephelometry, 
>90% of the chamber particles were found to be in the 1-2-/~m 
range. Sensitization was achieved after a daily 20-min exposure for 
a consecutive 10 d. Nonimmune control mice were exposed to PBS 
under the same conditions. Care of the animals was in accordance 
with institutional  guidelines. 
Lymphocyte Preparation  and Cell Transfer  Protocol.  Single  cell sus- 
pensions were prepared from spleen on day 12, 2 d after comple- 
tion  of the sensitization  protocol as described (10, 11). For the 
transfer experiments, VB8.1/8.2 and V/32 cells prepared from OVA- 
sensitized mice (V/38.1/8.2  and V/32 [OVA]) or from controls 
(VB8.1/8.2 and VB2 [PBS]) were isolated from spleen. T cells ex- 
pressing desired Vfl elements were purified by panning  on either 
KJ16 (V/38.1/8.2)-  or B20.6 (V/32)-coated tissue culture  flasks. 
After panning, the cells were expanded and subcultured with IL-2- 
(50 U/ml) and Ib4- (200 U/ml) containing culture medium (RPMI 
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3-4 d. Before cell transfer,  the cell populations were analyzed by 
flow cytometry. The enrichment procedure resulted in a 96-99.5% 
population of T cells expressing the particular VB TCR. The dis- 
tribution of CD4/CD8 cells was 4:1 in both the VB8 and VB2 
subsets.  The percentage of B cells was always <0.1%. Culture su- 
pernatants from expanded cells were free of total and anti-OVA 
IgG as analyzed by ELISA. 10  x  106 cells per mouse were trans- 
ferred by intravenous (tail  vein) infusion into syngeneic, nonim- 
munized mice. In cell mixture experiments, an equal number of 
10  x  106 V/38 and 10  x  106 VB2 cells was injected. Immediately 
after transfer,  the recipients were challenged with a single OVA 
nebulization for 20 min, which by itself did not induce anti-OVA 
Ig production  (10). 
Determination of Anti-OVA  Serum Antibody Levels.  Anti-OVA 
IgE and IgG serum antibody levels were measured by ELISA as 
described  (9).  Round-bottomed  microtiter  plates  (96-well  Im- 
munolon II; Dynatech Laboratories,  Burlingame, CA) were coated 
with 20/~g/ml OVA diluted in NaHCO3 buffer, pH 8.2.  After 
overnight incubation at 4~  plates were washed three times and 
blocked with Tris-BSA  (1%; wt/vol) buffer, pH 9.6,  for 2 h  at 
37~  Serum samples were diluted in 0.1 M Tris, BSA, 1% Tween 
buffer starting at a 1:20 dilution.  These and additional  twofold 
serial dilutions were added to the plates and incubated overnight 
at  4~  After  washing,  either  alkaline  phosphatase-conjugated 
monoclonal rat  anti-mouse IgE, IgG1 (Pharmingen Corp.,  San 
Diego, CA) or goat anti-mouse IgG (Sigma Chemical Co.) diluted 
in Tris, BSA,  1% Tween buffer was added for an additional 2 h. 
The reaction  was developed  with phosphatase substrate (Sigma 
Chemical Co.). Plates were read in a microplate autoreader (Bio- 
Rad Laboratories, Richmond,  CA) at 410 nm. 
The antibody levels of samples were compared with known stan- 
dards (9). The standard serum was a pool of serum collected from 
five OVA-sensitized  mice that demonstrated strongly positive skin 
reactions  to OVA.  The concentration  of anti-OVA IgE was ar- 
bitrarily assigned 1,000  ELISA units (EU).  For IgG, serum was 
pooled from mice immunized to OVA by intraperitoneal injection 
of 500/zg OVA/mouse. In this case, no positive skin reactions to 
OVA were found, and the concentration of IgG anti-OVA was ar- 
bitrarily assigned  1,000 EU. Analysis of ELISA data was performed 
with  the Microplate Manager software for the Macintosh com- 
puter (Bio-Rad Laboratories). 
Determination of Immediate Cutaneous Hypersensitivity.  Skin tests 
were performed as described (12) at the same time the serum was 
collected and AR was analyzed. Mice were injected (intradermally) 
with 20/zl of an OVA solution (500/~g/ml in PBS) or, as a nega- 
tive control,  the same volume of PBS. The positive control was 
compound 48/80, an inducer of mast cell degranulation. Reactions 
were scored as positive if the injection resulted in the formation 
of a wheal reaction with a diameter of a least 0.3 cm. In positive 
reactions, the wheal reached a maximum between 15 and 20 rain 
after injection and was approximately the same size as seen after 
injection of I  mg/ml compound 48/80.  No wheals developed  at 
the site of injection of the control solution.  A positive reaction 
to OVA was specific for this allergen, since injection of albumins 
(e.g.,  human serum albumin and BSA) from other species or an 
irrelevant allergen (e.g.,  ragweed) did not cause wheal formation 
in OVA-sensitized  mice. Immediate skin tests were performed in 
a blinded fashion. 
Analysis of  AR.  AR was measured in vitro by electrical stimu- 
lation of tracheal smooth muscle preparations as described (10). 
Analysis of AR was performed in the same animals and at the same 
time point when the serum was collected for measurements of Ig 
titers. Tracheal smooth muscle segments of'-0.5 cm in length were 
prepared from each individual mouse and placed in muscle baths 
that were perfused with a Krebs-Henseleit solution, oxygenated, 
and maintained at 37~  The tracheal segments were suspended 
by triangular supports transducing the force of contractions. Elec- 
trical field stimulation was delivered  by a stimulator ($44;  Grass 
Instrument Co., Quincy, MA) using an 8-mV, 2-ms pulse duration 
and increased  frequencies  (ranging from 0.5 to 40 Hz). Each stim- 
ulation was maintained until peak contractions were obtained. In 
all smooth muscle preparations, a current of 40 Hz resulted in max- 
imal contraction. For each preparation, the electrical  stimulation 
(Hz) causing 50% of the maximal contraction (ESs0) was calcu- 
lated from linear plots. The mean ESs0 (-+  SD) of nonimmunized 
mice was 4.18  _+ 0.24 Hz. This response was calculated as 100%. 
The values of the various experimental groups were compared with 
the control and were expressed as percent control ESs0. Analysis 
of AR and data calculations were performed in a blinded fashion. 
Statistical analysis  was performed by two-tailed student's t test. 
Depicted are mean  +_  SE for each group. 
Results and Discussion 
V38.1/8.2  and  V/32  T  cells  were  isolated  from  OVA- 
sensitized and nonimmunized control mice, expanded in the 
presence of IL-2 and IL-4, and were infused into syngeneic, 
naive BALB/c mice. This combination of lymphokines was 
chosen to expand the T  cell subsets since these factors play 
a central role in the growth  and differentiation  of different 
T  cell  subpopulations.  Another  advantage of this  protocol 
is that at the end of the expansion period the T  cells were 
activated,  a requirement  for the induction  of Ig production 
by B cells. B cells were not present in the infusate since <0.1% 
of the cells were identified as B cells by flow cytometry. Fur- 
ther, in culture supernatants collected after expansion of the 
lymphocytes, neither allergen nonspecific nor anti-OVA IgE 
antibody  was  detectable. 
Immediately after cell transfer the recipients were challenged 
with  a  single  (20-min)  exposure  to  OVA by nebulization. 
As  shown  earlier,  this  challenge by itself had  no effect on 
IgE production and changes in AR (10). 5 d later serum was 
collected and IgE anti-OVA titers were measured by ELISA. 
As shown in Table 1, primary sensitization to OVA resulted 
in  an increase in  IgG anti-OVA  antibody  titers.  Nonsensi- 
tized mice did not develop an IgE anti-OVA response. When 
VB8.1/8.2 T  cells from primary, sensitized mice were trans- 
ferred into  naive recipients,  an increase in  serum IgE anti- 
OVA was detected.  The transfer of 10  x  106 cells resulted 
in a response that was about half of that observed in the serum 
of primary,  donor  mice.  The transfer of the  same number 
ofV/38.1/8.2 T cells from nonimmunized mice was without 
effect. In contrast to the results with V38 + T  cells, transfer 
of V32  T  cells from OVA-sensitized  mice did not  lead  to 
any increase in IgE anti-OVA antibody. Cotransfer of a mix- 
ture of 10  x  104 V~8.1/8.2  plus  10  x  106 V32 cells from 
sensitized (but not nonimmune) mice markedly reduced the 
levels of OVA-specific IgE antibody when compared with the 
transfer  of V/38.1/8.2  T  cells  alone. 
At  the  same time  that  the  IgE  anti-OVA  response  was 
elevated in the primary, sensitized animals, only a relatively 
low  IgG anti-OVA  response was detected  in  the  serum  of 
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Anti-OVA 
Donor  Cells transferred 
exposure  to  recipient  IgE  IgG  IgG1 
EU 
OVA  -  1,348  -+  468  321  +  39  50  -+  10 
PBS  -  <20  <20  <20 
OVA  VB8.1/8.2  630  -+  54  354  -+  47  <20 
PBS  VB8.1/8.2  120  -+  36  103  _+  39  <20 
OVA  V~2  <20  121  +_  5  <20 
OVA  V/32  +  V/~/8.1/8.2  125  _+  15  320  _+  54  <20 
2 d after completion of the 10-d course (20 min each day) of OVA sensitization  through the airways,  serum was collected and analyzed for anti-OVA 
Ig production by ELISA as described (9). Nonimmune control mice were exposed to PBS for the same period of time. In the transfer  experiments, 
V38.1/8.2 and VB2 cells prepared  from OVA-sensitized mice (8.1/8.2 and V/~2 [OVA]) or from controls (8.1/8.2 and V32 [PBS]) were obtained 
from spleen.  Spleens were prepared  on day  12,  2 d after  completion of the sensitization  protocol.  10  x  106 cells per mouse were transferred  by 
intravenous (tail vein) infusion  into syngeneic,  nonimmunized mice.  In cell mixture experiments,  an equal number of 10  x  106 VB8 and  10  x 
106 V32 cells was injected.  Immediately after transfer,  the recipients were challenged with a single OVA nebulization for 20 min, which by itself 
did not induce anti-OVA ig production (10). 5 d later,  serum was collected and analyzed for IgE, IgG, and IgG1 anti-OVA production by ELISA 
and expressed as units per milliliter serum.  Serum from each animal was  analyzed individually  in a blinded  fashion.  The same mice were used for 
experiments depicted in Fig. 1 and Table 2. For each experimental  group mean  +  SD are depicted.  Statistical analysis was performed by two-tailed 
student's t test. 
these mice. Particularly noteworthy is the fact that an IgG1 
anti-OVA response was absent at this early time point, but 
increased over time (by day 28)  (11). This pattern  of anti- 
body development was also seen after the transfer of V~8.1/8.2 
cells,  namely a relatively low IgG anti-OVA response,  and 
no IgG1 anti-OVA antibodies were detected. The transfer of 
V~2  T  cells  did  not  result  in  an  IgG  response,  and  the 
cotransfer of both cell populations had no effect on IgG anti- 
OVA responses other than those observed with the transfer 
of VB8 T  cells  alone (Table  1). 
The appearance of an IgE anti-OVA response in the recip- 
ients was accompanied by the acquisition of immediate cuta- 
neous hypersensitivity responses to OVA, defined by the de- 
velopment  of immediate  wheal  reactions  15-20  min  after 
intradermal  injection of OVA. Earlier studies demonstrated 
the reliability and sensitivity of this approach for screening 
IgE-mediated cutaneous reactivity (12). In addition, these re- 
sponses were specific to the allergen used as injection of ir- 
relevant allergens or control solutions did not generate any 
immediate responses. Positive reactions to OVA were elicited 
only when VB8.1/8.2 T cells from OVA-sensitized  mice were 
transferred into recipient mice (Table 2). In recipients of the 
combination of VB8.1/8.2 and V32 cells, the proportion of 
animals reacting to intradermal  injection of OVA was markedly 
reduced. These data demonstrated that transfer of T cells ex- 
pressing V~8.1/8.2,  isolated from allergen-sensitized mice, 
can induce allergen-specific IgE production  and immediate 
cutaneous hypersensitivity in recipients of these cells. V~2- 
expressing T  cells  from sensitized  animals  significantly re- 
duced these responses when cotransferred  with the VB8 T cells. 
The response of tracheal  smooth muscle preparations  to 
electrical field stimulation represents one means for assessing 
AR in vitro (10). We assessed AR in this way to determine 
the role of transferred lymphocytes in altering airways func- 
tion. At the same time that IgE was measured in the serum 
of sensitized  animals,  we demonstrated  an increase in AR 
when tracheal smooth muscle preparations were exposed to 
Table  2.  Transfer of Immediate Cutaneous Hypersensitivity with 
V~8.1/8.2  T  Cells 
Cells transferred  Positive skin 
Donor exposure  to recipient  tests 
% 
OVA  -  31/27  84 
PBS  -  0/22  0 
OVA  VB8.1/8.2  8/9  88 
PBS  vB8.1/8.2  0/9  0 
OVA  Vfl2  2/10  20 
OVA  VB2  +  V~8.1/8.2  2/10  20 
Immediate cutaneous  hypersensitivity  was determined at the same time 
AR was measured and serum was taken for antibody titer analysis. Ex- 
pressed are the number and percentage  of mice with positive  reactions 
to OVA. In all mice, the positive control solution compound 48/80 yielded 
positive reactions,  and  tests  with PBS were negative. 
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Figure  1.  Analysis of AR in OVA-sensitized mice and recipients  of 
VB8.1/8.2 and VB2 T cells. AR was measured in vitro by electrical field 
stimulation of tracheal smooth muscle preparations. Analysis of AR was 
performed in the same animals and at the same time point when the serum 
was collected for measurements  of Ig titers. Each stimulation  was main- 
tained until peak contractions  were obtained. In all smooth muscle prepa- 
rations, a current of 40 Hz resulted in maximal contraction.  For each prep- 
aration,  the ESs0 was calculated from linear plots. The mean ESs0 (-+ SE) 
of nonimmunized mice was 4.18 _+ 0.24 Hz. This response was calculated 
as 100%. The values of the various experimental  groups  were compared 
with the control and were expressed as percent control ESs0. Analysis of 
AR and data calculations were performed in a blinded fashion. Statistical 
analysis was performed by two-tailed  student's  t test. Depicted are mean 
+  SE for each group. 
electrical field stimulation. In contrast to nonimmunized con- 
trols, OVA-sensitized mice developed increases in AlL, indi- 
cated by a decrease in the mean ESs0 from 4.18 to 2.73 Hz. 
This drop in ESs0 of 30-40%  was significant (Fig.  1) and 
was in the range found by other investigators using similar 
methodology in a variety of different animal systems (13, 14). 
In parallel to the data obtained for IgE production,  the 
transfer of Vfl8.1/8.2 T  cells from sensitized animals into 
naive,  syngeneic recipients resulted in a similar increase in 
AR in these animals, in the same range observed with the 
primary, sensitized mice (Fig. 1). The lowest effective number 
of T  cells capable of transferring altered AR was 10  x  106 
Vfl8.1/8.2 T cells. Transfer of 5  x  106 cells did not lead to 
changes in AR (data not shown). Control mice that received 
Vfl8.1/8.2 T cells from nonimmune mice (up to 30  x  106) 
developed a decrease rather than any increase in AR. A similar 
effect was observed after the transfer of Vfl2 T  cells from 
OVA-sensitized mice. This decrease in AlL is unexplained at 
present. When Vfl8.1/8.2 T cells from OVA-sensitized  mice 
were mixed with an equal number of Vfl2 T  cells (10  x 
106) from sensitized (but not from nonimmune) animals and 
transferred, the increases  in AlL observed with transfer of 
Vfl8.1/8.2 T cells alone were abolished. For these effects as 
well as for the induction of the IgE response, the single OVA 
challenge was required after the cell infusion, since only mar- 
ginal changes were observed when the single OVA nebuliza- 
tion was omitted (data not shown). 
To further demonstrate the specificity of these T cell effects, 
the  isolated  lymphocytes  were  preincubated  with  anti- 
Vfl8.1/8.2 (KJ16) antibody before cell transfer. Table 3 sum- 
marizes the effect of this procedure on IgE production, im- 
mediate cutaneous hypersensitivity, and AlL. Anti-OVA IgE 
production was inhibited by >80%  when compared with 
animals receiving V~8.1/8.2 cells treated with an anti-Vfl2 
antibody of the same isotype. Analysis of immediate cuta- 
neous responses revealed that only 2 of 10 recipients receiving 
cells treated with KJ16 antibody had a positive reaction to 
OVA compared with six of six animals who received cells 
treated with the anti-Vfl2 antibody. Also,  animals receiving 
VB8.1/8.2  T  cells treated with KJ16  antibody did not de- 
velop  any  appreciable  increases  in  AlL.  The  mechanism 
whereby pretreatment of cells with KJ16 antibody abolishes 
these responses is unclear, but binding of KJ16 antibody may 
prevent TCIL-MHC interaction in the recipients. 
This study provides evidence that IgE production and de- 
velopment of immediate cutaneous hypersensitivity reactions 
Table  3.  Effect of Pretreatment of Transferred T  cells with Anti-V~8.1/8.2  or Anti-Vfl2  Antibody 
Treatment  IgE anti-OVA  Positive skin test  ESs0 
Anti-V32 antibody 
(n  =  6) 
Anti-Vfl8.1/8.2 antibody 
(n  =  8) 
U/ml  Hz 
1,224  _+  314  6/6  (100%)  2.79  _+  0.25 
256  _+  138  1/4  (25%)  3.75  _+  0.32 
Before cell transfer,  Vfl8.1/8.2 T cells were incubated  with mAb KJ16 (10/~g/ml) for 30 min at 4~  Flow cytometry (staining  with biotinylated 
KJ16) indicated  that this procedure  resulted in binding of this antibody  to all V38.1/8.2 T cells. As a control Vfl8.1/8.2 were also incubated  with 
anti-V32 antibody (10/zg/ml) for 30 min at 4~  This antibody  is of the same isotype as the KJ16 antibody.  Cells were then transferred as described 
in Fig. 1.5 d later, serum was collected and analyzed for IgE anti-OVA responses. At the same time, skin tests were performed  and AR was deter- 
mined using tracheal smooth muscle preparations.  Analyses of ELISA titers, skin tests, and AR were performed  as described in Materials and Methods 
in a blinded fashion. 
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opment of increased AR, can be regulated by T cell subpopu- 
lations that are only distinguished by the pattern of V3 ele- 
ments expressed on the TCR.  The same T  cell subset that 
can transfer allergen-specific  IgE production also transfers  the 
increase in AR. It is presently unclear if the increases in AR 
are causally linked to the presence of IgE or whether both 
events are independent of each other. However, both events 
are regulated by the same T  cells in a positive (V38.1/8.2) 
as well as negative (V32) direction. This emphasizes the close 
relationship between the presence of certain antigen-specific 
T cell subsets, the regulation of IgE production, and changes 
in AR. This relationship between distinct V3-expressing T 
cell subsets is further supported by the findings in SJL/J mice. 
This strain  of mice, which lacks VB8 T  cells,  failed to re- 
spond to antigen challenge with specific IgE responses, cuta- 
neous reactivity, or changes in AR (10,  12). At the present 
time it is unclear how these responses are linked  to VBS- 
expressing T  cells  or their regulation  by V~2 T  cells.  Al- 
though V/~8 cells from both sensitized as well as control mice 
were similarly activated by the panning and expansion pro- 
cedure, only V~8 cells from antigen-exposed mice demon- 
strated  stimulatory effects on IgE production  and AR. 
The effects of the different V/~-expressing T  cell subsets 
may be related to different patterns of cytokine production. 
It is conceivable that different V3-expressing T cell subsets 
exhibit specific patterns  of cytokine production.  IL-4 is es- 
sential for the stimulation  of IgE production,  whereas the 
T cell product IFN-3' is known to inhibit IL-4-induced IgE 
production (6). V38 and V32 T cells may thus differ in the 
pattern of secreted cytokines. In freshly isolated CD4 T cells, 
such differences among T cell subsets have not been observed 
but they have been demonstrated in T  cell clones (Thl  and 
Th2 clones) (15).  It would be surprising  that V38 T  cells 
in general are characterized as high II.,4 producers. A more 
likely possibility is that  the differential effects of V38 and 
V32 T cells are related to antigen specificity and/or antigen 
presentation. Similar preferential usage of a particular V3 re- 
gion gene segment has been reported for human T cells reac- 
tive with a specific tetanus toxin-derived peptide. The same 
V3 segment was used irrespective of the expression of different 
MHC class II antigens  on APC  (16).  The presentation  of 
specific immunogenic epitopes on different APC may drive 
subsets ofT cells along different pathways with Th2- or Thl- 
like activities. Thus, certain cytokine patterns may be assigned 
to specific VB-bearing T  cell subsets. It now becomes im- 
portant to examine whether sensitization to other allergens 
also leads to a selective expansion of distinct VB-bearing T 
cell  subsets and  whether  such  subpopulations  also play a 
differential role in the regulation of IgE production and AR. 
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